Probiotics (Lactobacillus Rhamnosus) in Reducing Glucose Intolerance During and After Pregnancy (GRIP)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01436448|
Recruitment Status : Unknown
Verified September 2011 by Bilal Ahmed, Aga Khan University.
Recruitment status was: Not yet recruiting
First Posted : September 19, 2011
Last Update Posted : September 20, 2011
Introduction: The overall aim of the study is to assess the efficacy of Lactobacillus Rhamnosus in reducing glucose intolerance during and after pregnancy. A second objective of the study is to determine the feasibility, compliance and safety of Lactobacillus Rhamnosus among this cohort. Within this goal is to determine whether the investigators can enroll women at high risk for developing Gestational Diabetes Mellitus (GDM) and follow them out at regular antenatal visits and 6-weeks post partum.
Women with GDM are, 7 times more at risk of developing type 2 diabetes compared with those who had a normo- glycaemic pregnancy. The population attributable risk for type 2 diabetes mellitus (DM) in women with GDM is high, and around 30 - 50% women with GDM converts into type 2 (DM) which is associated with pre-mature morbidity, mortality and high economic burden. It is evident that untreated GDM is associated with higher incidence of complications during pregnancy and increases the risk of perinatal mortality and infant morbidity. The prevalence of GDM in Pakistan is around 8%, comparatively higher than other South Asian countries. Therefore, interventions that can improve glucose regulation during pregnancy are highly important.
Probiotics, the live micro-organisms, have shown promising results in regulating glucose metabolism among pregnant mice. The effect of Probiotics on glucose metabolism is attributable to their immuno-regulatory properties. They elicit powerful anti-inflammatory capabilities by inhibiting the NF-kB pathway, which mediates microbial activation of the immune system. Further, they diminish both fermentation of polysaccharides and induction of fasting-induced adipocyte factor gene transcription. The safety of Lactobacillus Rhamnosus among pregnant women is already established in other diseases.
A placebo controlled trial from Finland on pregnant females randomized to receive either dietary counseling and Probiotics (Lactobacillus Rhamnosus), concluded improved glucose tolerance as compared to the placebo group [OR 0.31 (95% CI 0.12, 0.78)]. However, this study could not determine the sole effects of probiotics in reducing glucose intolerance. Nevertheless, no studies on the role of Lactobacillus Rhamnosus in regulating glucose intolerance have been conducted in any other part of the world yet. Therefore, a pilot trial to see the efficacy, compliance and feasibility of Lactobacillus Rhamnosus among pregnant females is imperative. The objectives of the investigators study are:
- To assess the efficacy of Probiotics Lactobacillus Rhamnosus (1010 Colony forming Units (CFU)/day) in reducing glucose intolerance among pregnant women attending antenatal clinic of Karachi-Pakistan.
- To assess the feasibility, compliance and safety of conducting a double blind, placebo controlled randomized trial of Lactobacillus Rhamnosus by recruiting high risk women during pregnancy attending antenatal clinics and following them up 6 weeks postpartum in Karachi-Pakistan.
Methods: For the pilot trial, women will be recruited from antenatal hospital of the city, during 12-14 weeks of gestation.
Study Design: The study will be double blind randomized, placebo controlled trial. Randomization will be done by blocked method. The dose of 1010 Colony forming Units (CFU) once daily till delivery will be given orally.
Study Endpoints and Ascertainment: Baseline information will be comprised of socioeconomic status, parity, gravida, blood pressure and obstetric history etc. The study endpoint comprises of efficacy, feasibility, compliance and safety and will be ascertained at monthly follow-up, during week 24 - 28, and 6 weeks post partum. Efficacy will be ascertained by Oral Glucose Tolerance Test (OGTT) performed at randomization and during 24-28 weeks of gestation. Feasibility and compliance will be assessed through recruitment rate, drop-out rate, reasons for drop-out, non-participation and empty drug sachet count.
|Condition or disease||Intervention/treatment||Phase|
|Glucose Intolerance Pregnancy||Drug: Probiotics Lactobacillus Rhamnosus||Phase 3|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||200 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Triple (Participant, Care Provider, Investigator)|
|Official Title:||Effects of Probiotics (Lactobacillus Rhamnosus) In Reducing Glucose Intolerance During and After Pregnancy: A Double Blind Randomized Controlled Trial in Antenatal Clinic of Karachi-Pakistan (GRIP)|
|Study Start Date :||October 2011|
|Estimated Primary Completion Date :||November 2012|
|Estimated Study Completion Date :||May 2013|
Experimental: Probiotics Lactobacillus Rhamnosus
dose of 1010 Colony forming Units (CFU) once daily till delivery will be given orally
Drug: Probiotics Lactobacillus Rhamnosus
Probiotics Lactobacillus Rhamnosus (1010 Colony forming Units (CFU)/day)
No Intervention: Placebo
Microcrystalline cellulose/d each, up till deliver
- Glucose Intolerance [ Time Frame: 24-28 weeks of pregnancy ]Glucose Intolerance. Glucose intolerance will be assessed in accordance with ADA guidelines by OGTT. OGTT will be performed during 24-28 weeks of pregnancy
- Glucose Intolerance [ Time Frame: 6 to 8 weeks post partum ]Glucose Intolerance. Glucose intolerance will be assessed in accordance with ADA guidelines by OGTT. OGTT will be performed during 6 to 8 weeks post partum
- Feasibility [ Time Frame: 36 weeks ]
- Process of recruitment rate assessed at monthly antenatal visit
- recruitment rate rate assessed at monthly antenatal visit
- Reasons for non-participation rate assessed at monthly antenatal visit
- Compliance [ Time Frame: 36 weeks ]
- the compliance rate assessed at monthly antenatal visit
- side effects rate assessed at monthly antenatal visit
- drop-out rate rate assessed at monthly antenatal visit
- reasons for drop-out rate assessed at monthly antenatal visit
- Maternal safety [ Time Frame: at the time of delivery till 42 weeks postpartum ]
MATERNAL OUTCOMES:( :( assessed at the time of delivery and postpartum)
Maternal Mortality Maternal Weight Gain Preeclampsia Induction of labor Mode of Delivery
- FETAL/NEONATAL safety [ Time Frame: assessed at the time of delivery till 6-8 weeks postpartum ]
Death This will include:
Still births Neonatal death Pre-term birth. Birth Trauma Macrosomia Small for Gestational Age Polyhydramnios Recurrent Hypoglycemia Large for Gestational Age Shoulder Dystocia 5-minute Apgar score: <7 Hyperbilrubinemia Respiratory Distress NICU Admission
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01436448
|Aga Khan Hospital for Garden||Active, not recruiting|
|Karachi, Sind, Pakistan, 74800|
|Principal Investigator:||Bilal Ahmed, MSc||Aga Khan University|
|Study Chair:||Abdul Jabbar, MBBS, FRCP||Aga Khan University|
|Principal Investigator:||Kashmira Nanji, MSc||Aga Khan University|
|OverallOfficial:||Ali Khowaja, FRCS||Aga Khan University|
|OverallOfficial:||Sarah Saleem, MBBS, MSc||Aga Khan University|
|OverallOfficial:||Rozina Sikandar, MBBS, FCPS||Aga Khan University|